Clonal hematopoiesis in people with advanced HIV and associated inflammatory syndromes.

AIDS/HIV Aging Clonal selection Macrophages T cells

Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
02 Apr 2024
Historique:
medline: 2 4 2024
pubmed: 2 4 2024
entrez: 2 4 2024
Statut: aheadofprint

Résumé

People with HIV (PWH) have a higher age-adjusted mortality due to chronic immune activation and age-related comorbidities. PWH also have higher rates of clonal hematopoiesis (CH) than age-matched non-HIV cohorts, however, risk factors influencing the development and expansion of CH in PWH remain incompletely explored. We investigated the relationship between CH, immune biomarkers, and HIV-associated risk factors (CD4, CD8 T-cells, nadir CD4 count, opportunistic infections [OIs], and immune reconstitution inflammatory syndrome [IRIS]) in a diverse cohort of 197-PWH with median age of 42-years, using a 56-gene panel. Seventy-nine percent had a CD4 nadir < 200, 58.9% had prior OIs, and 34.5% had a history of IRIS. The prevalence of CH was high (27.4%), even in younger individuals, and CD8 T-cells and nadir CD4 counts strongly associated with CH after controlling for age. A history of IRIS was associated with CH in a subgroup analysis of ≥ 35-years-old patients. Inflammatory biomarkers were higher in CH carriers compared to non-carriers supporting a dysregulated immune state. These findings suggest PWH with low nadir CD4 and/or inflammatory complications may be at high risk of CH regardless of age and represent a high-risk group that could benefit from risk reduction and potentially targeted immunomodulation.

Identifiants

pubmed: 38564303
pii: 174783
doi: 10.1172/jci.insight.174783
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Joseph M Rocco (JM)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Yifan Zhou (Y)

Translational Stem Cell Biology Branch, National Heart, Lung and Blood Inst, NIH, Bethesda, United States of America.

Nicholas S Liu (NS)

Translational Stem Cell Biology Branch, National Heart, Lung and Blood Inst, NIH, Bethesda, United States of America.

Elizabeth Laidlaw (E)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Frances Galindo (F)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Megan V Anderson (MV)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Adam Rupert (A)

Leidos Biomedical Research Core, Frederick, United States of America.

Silvia Lucena Lage (S)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Ana M Ortega-Villa (AM)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Shiqin Yu (S)

Translational Stem Cell Biology Branch, National Heart, Lung and Blood Inst, NIH, Bethesda, United States of America.

Andrea Lisco (A)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Maura Manion (M)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

George S Vassiliou (GS)

Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.

Cynthia E Dunbar (CE)

Translational Stem Cell Biology Branch, National Heart, Lung and Blood Inst, NIH, Bethesda, United States of America.

Irini Sereti (I)

National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States of America.

Classifications MeSH